No Data
Express News | Natera Shares Are Trading Lower. The Company Reported Results From Its DEFINE-HT Clinical Trial
Natera: Results Of DEFINE-HT Clinical Trial Shows Prospera Heart Is Predictive Of Clinical Outcomes And Outperforms Biopsy In Predicting Graft Dysfunction
Natera Announces That Its Ultra-Sensitive Signatera Genome Assay Is Now Broadly Available To Physicians In The United States.
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera Genome MRD Test
Natera To Present Data From 8 Studies at 2025 AACR Annual Meeting
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today